Cytokinetics (CYTK) Cash from Operations (2016 - 2025)
Historic Cash from Operations for Cytokinetics (CYTK) over the last 15 years, with Q4 2024 value amounting to -$65.6 million.
- Cytokinetics' Cash from Operations rose 1142.27% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$395.9 million, marking a year-over-year increase of 444.88%. This contributed to the annual value of -$395.9 million for FY2024, which is 444.88% up from last year.
- Latest data reveals that Cytokinetics reported Cash from Operations of -$65.6 million as of Q4 2024, which was up 1142.27% from -$101.5 million recorded in Q3 2024.
- Cytokinetics' Cash from Operations' 5-year high stood at $52.2 million during Q4 2020, with a 5-year trough of -$129.5 million in Q1 2024.
- For the 5-year period, Cytokinetics' Cash from Operations averaged around -$62.2 million, with its median value being -$69.8 million (2023).
- Per our database at Business Quant, Cytokinetics' Cash from Operations surged by 37368.14% in 2020 and then plummeted by 36985.45% in 2021.
- Cytokinetics' Cash from Operations (Quarter) stood at $52.2 million in 2020, then tumbled by 185.79% to -$44.7 million in 2021, then tumbled by 119.48% to -$98.2 million in 2022, then rose by 24.6% to -$74.0 million in 2023, then increased by 11.42% to -$65.6 million in 2024.
- Its Cash from Operations stands at -$65.6 million for Q4 2024, versus -$101.5 million for Q3 2024 and -$99.3 million for Q2 2024.